CARDIONOVUM GmbH
Mark Pruefert is currently the Chief Commercial Officer at CARDIONOVUM GmbH since November 2020. Prior to this role, Mark was the Global Sales and Marketing Director at iVascular from September 2011 to October 2020 and at IHT from January 2009 to September 2011. Mark also worked as the Internal Sales and Marketing Consultant and Hospital Sales Specialist at Laboratorios Menarini from January 2003 to December 2008. Mark holds a Master in Marketing from Esade, a Master of Business Administration from Collège des Ingénieurs, and a degree in Chemical Engineering from Universitat Ramon Llull.
This person is not in any offices
CARDIONOVUM GmbH
CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease. The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products. Pioneers in medical devices. The worldwide first CE-approved DCB. With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices. “Live Deserves the Best”